Clinical review report Netupitant/palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma)
The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of Netupitant/palonosetron (NEPA) in preventing chemotherapy-induced nausea and vomiting (CINV) for patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemot...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820282506719 |
| Sumario: | The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of Netupitant/palonosetron (NEPA) in preventing chemotherapy-induced nausea and vomiting (CINV) for patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). |
|---|---|
| Descripción Física: | 1 online resource (1 PDF file (96 pages)) : illustrations |
